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Objectives. To investigate the possible role of cystatin C in eye biological fluids locally and in serum and
lactoferrin revealing anti-tumor activity in eye tumor development.
Background. The increased number of eye tumors was registered recently not only in the countries with high
insolation, but also in the northern countries including Russia (11 cases per million of population). Search for
new biological markers is important for diagnosis and prognosis in eye tumors. Cystatin C, an endogenous
inhibitor of cysteine proteases, plays an important protective role in several tumors. Lactoferrin was shown to
express anti-tumor and antiviral activities. It was hypothesized that cystatin C and lactoferrin could serve as
possible biomarkers in the diagnosis of malignant and benign eye tumors.
Study design. A total of 54 patients with choroidal melanoma and benign eye tumors were examined (part
of them undergoing surgical treatment). Serum, tear fluid and intraocular fluid samples obtained from
the anterior chamber of eyes in patients with choroidal melanoma were studied.
Methods. Cystatin C concentration in serum and eye biological fluids was measured by commercial ELISA
kits for human (BioVendor, Czechia); lactoferrin concentration  by Lactoferrin-strip D 4106 ELISA test
systems (Vector-BEST, Novosibirsk Region, Russia).
Results. Cystatin C concentration in serum of healthy persons was significantly higher as compared to tear
and intraocular fluids. In patients with choroidal melanoma, increased cystatin C concentration was similar
in tear fluid of both the eyes. Lactoferrin level in tear fluid of healthy persons was significantly higher than its
serum level. Significantly increased lactoferrin concentration in tear fluid was noted in patients with benign
and malignant eye tumors.
Conclusion. Increased level of cystatin C in tear fluid seems to be a possible diagnostic factor in the eye tumors
studied. However, it does not allow us to differentiate between malignant and benign eye tumors. Similar
changes were noted for lactoferrin in tear fluid.
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C
ystatins belong to the group of endogenous
inhibitors of cysteine proteases, which are im-
portant in clinical and experimental medicine
(1,2). The main functions of cystatins are related to the
inhibition of cysteine proteases, cell proliferation, cell
migration and cell differentiation (3,4). Cystatins A and
B (belonging to type 1) are mainly intracellular inhibi-
tors; cystatins C, D, E/M, F, G, S, SN and SA are
extracellular cystatins (belonging to type 2). Cystatins
SA, S and SN were found primarily in saliva. Cystatins S
and SN can also be expressed in tears, urine and seminal
fluid (4). Cystatin C was shown to play a role in protein
catabolism, cancer development, regulation of hormone
processing and bone resorption, modulating inflamma-
tion (5,6). Increased cystatin C level has been found in the
serum of patients with several inflammatory diseases,
such as colorectal tumors with metastases (7). Cystatin C
as well as cystatins B, SN, SA and S was identified in tear
fluid (4). Among the cystatin type 2 superfamily, cystatin
C is the most studied; it is expressed in brain, thymus and
epididymis. Cystatin C is produced at a constant rate by
all types of cells and localized mainly in extracellular
fluids; the high concentration was shown in cerebrospinal
fluid, and in lower concentrations in milk, synovial fluid,
serum, urine and bile (8,9). In eye fluids (less studied as
compared to other biological fluids), cystatin C as a
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inhibiting all cysteine proteases, such as cathepsins B,
L, S (1012). It was shown recently that some members
of the cystatin superfamily (cystatin A) have antiapopto-
tic properties linked with neoplastic changes in squamous
cell epithelium. Therefore, it has been proposed as a
diagnostic and prognostic marker of lung cancer (13).
Recently, cystatin C was suggested as a prognostic factor
in multiple myeloma (14), in the diagnostics of early-stage
and inflammatory breast cancer (15). However, the role
of cystatin C in eye tumors has not been studied in detail.
Lactoferrin is a 78,000-Da metal-binding single-chain
glycoprotein found in milk, tear fluid and other biological
exocrine secretions (16,17). Lactoferrin has bacteriostatic
properties in vitro and some anti-tumor activity (16,18).
Since the human lactoferrin gene has been cloned, over-
expression and large-scale lactoferrin production are now
possible.
Choroidal melanoma is one of the most aggressive
malignant and most observed among eye tumors. Until
now, there have been difficulties in differential diagnostics
ofchoroidal melanomawithnumerous eye tumors, mainly
with benign tumors, as well as with so-called pseudo-
tumorous disorders. Pseudo-tumors included disciform
macular degeneration, sub-retinal hemorrhage, Coats’
disease (very rare congenital, nonhereditary eye disorder)
and so on. Therefore, the search for possible new tumor
biomarkers among different types of eye tumors is still
important. The aim is to investigate the role of cystatin C
in eye tear fluid and anterior camera of eye locally, and in
serum and lactoferrin, revealing anti-tumor activity in eye
tumor development (choroidal melanoma).
Materials and methods
Design of the study
A total of 43 patients with choroidal melanoma and 11
with benign eye tumors and pseudo-tumorous disorders
(undergoing examination and treatment in Fedorov’s
Centre for Eye Surgery) and 24 controls (healthy persons,
medical doctors) were enrolled in this study. All patients
were undergoing standard ophthalmologic examina-
tions, including visiometric analysis, perimetry and visual
field research, tonometry, biomicroscopic examination,
ophthalmoscope examination and ultrasound exam (B-
scanning). In several special cases, the following addi-
tional methods were used: ultrasound eye biomicroscopy,
optical coherent tomography of retina, duplex eye scan
with the dopplerography examination of vessels.
The group of patients with choroidal melanoma in-
cluded 43 persons aged 2880 (56.9915 years; males: 15,
females: 28). Their vision was from 0 to 1.0. In all patients,
ultrasound examination revealed plus-tissue (with low or
middle echo-density) growing from the vessels. In most of
the patients (42), the tumor process was noted in one eye,
in 1 patient  in both eyes (simultaneously with breast
cancer). The eye tumor length (height) was from 1.2 to
14.7 mm, diameter of the tumor basement  from 8.2 to
27.6 mm. In 17 cases with large-sized tumors, surgery was
carried out (enucleating). Histological study revealed the
appearance of round-cellular melanoblastoma (7 cases),
spindle-cell malignant melanoma (6 cases), epithelial type
of melanoblastoma (2 cases) and melanoblastoma of the
mixed type (2 cases). Benign eye tumors and pseudo-tumors
group included 11 persons, aged 4274 (62.399.8 years);
among them 1 male and 10 females. The patients with
the following diagnosis were included in this group: age-
related macular degeneration  3 (vision from 0.001 to
0.1), sub-retinal hemorrhage  3 (vision from 0.001 to
0.01), iris-nevus syndrome (nevus of iridescent)  2 (vision
1.0) and nevus chorioidea  3 patients (vision 1.0).
Ultrasound scanning revealed plus-tissue syndrome, with
increased tissue from 0.5 to 4.7 mm with different echo-
densities. In 4 patients, duplex scanning with dopplero-
graphy examination did not reveal any plus-tissue and
changes in blood vessels. Control group  24 healthy
persons without ophthalmologic disorders, 2049 years
old (22915) were used as a control. Four patients with
cataracts aged 5881 were included in this group when
uptake of anterior camera fluid was carried out during
surgery. In addition, as a control for the study of serum
cystatin C, 10 healthy persons aged 5165 years were
included.
Sample collection
Tear samples were collected using 10-mL capillary tubes
without touching the eye globe or the lid. Intraocular
fluid was taken from anterior eye camera during surgery.
Serum was obtained after centrifuging blood samples at
3000g for 20 min at 48C (Eppendorf centrifuge 5415R,
Hamburg, Germany) and stored at 708C until analysis.
Cystatin C concentration in eye biological fluids and
serumwasmeasuredbycommercialELISAkitsforhuman
cystatin C (BioVendor, Czechia). The antibodies used in
ELISA are specific for human cystatin C. Analytical limit
ofdetection(ALD)ofcystatinCwas0.2ng/mL.Detection
of cystatin C did not interfere with hemoglobin (1.0 mg/
mL), bilirubin and triglycerides (5.0 mmol/L). The results
were expressed in nanogram per milliliter.
Lactoferrin concentration was assayed by commercial
ELISA kits (Vector-BEST, Novosibirsk Region, Russia)
according to the producer’s recommendations. The results
were expressed in nanogram per milliliter.
Statistical analysis
All values were reported as the mean9SEM. The results
were analyzed for statistically significant differences,
using MannWhitney criteria and Student’s t-test.
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Cystatin C concentration in the serum of healthy persons
(950.4921.2 ng/mL) was significantly higher (pB0.001)
as compared to tear (371.3925.7 ng/mL) and intraocular
fluids (765.6991.1 ng/mL, pB0.05). Among eye biologi-
calfluidsstudied,cystatinClevelwashigherinintraocular
anterior camera fluid as compared to tears (pB0.001)
(Table I). Therefore, concentration of cysteine protease
inhibitor was presented as follows: serum  intraocular
fluid  tears.
Choroidal melanoma
Tear fluid cystatin C level in both the eyes increased
(pB0.001), whereas concentration of this inhibitor in
anterior camera fluid decreased (pB0.05) as compared to
the control group (Table I). In choroidal melanoma,
cystatin C level was increased similarly in the tear fluid of
both the eyes (with and without tumor) versus control
(Table I). Cystatin C concentration is serum was sig-
nificantly increased (pB0.05) in choroidal melanoma.
Therefore, in patients with choroidal melanoma cystatin
C concentration was elevated in the tear fluid of both the
eyes (with tumor and without tumor), whereas in serum
similar changes were less prominent.
Lactoferrin concentration in tear fluid of healthy per-
sons (Table II) was significantly, approximately 10 times,
higher than lactoferrin levels in the serum of the control
(8001200 ng/mL) group. In anterior camera fluid of the
control group, lactoferrin concentration was significantly
(pB0.05) lower compared to that of the tear fluid and
serum (Table II). Increased lactoferrin concentration was
noted in tear fluid in patients with both benign (pB0.05)
and malignant eye tumors (pB0.05) and in anterior
camera fluid (pB0.05) in choroidal melanoma (Table II).
In patients with choroidal melanoma, an increased level
of lactoferrin was shown both in tear fluid of a tumor-
damaged eye and tear fluid of an eye without tumor
(Table II). Therewas no differencebetween increased level
of lactoferrin in tear fluids of patients with choroidal
melanoma and benign eye tumors (Table II). The role of
lactoferrin in eye tumor has not been studied enough until
now. Recently, in some other tumors (breast cancer
phenotypes), lactoferrin was shown to contribute to the
development and invasiveness of this disorder (19).
Discussion
The search for new non-invasive markers and predictors
of tumors of different localization is important for clinical
oncology, especially in rare tumors, such as melanoblas-
toma chorioidea, where it is impossible to get biopsy
material. Moreover, this tumor can be treated only
surgically (enucleation) at present, and early diagnosis is
essential. Until now, the biological markers of melano-
blastoma chorioidea arenot known. The tear fluids have a
special interest (availability of this biological fluid) for
searching biological markers. According to hypothesis,
many tumors to secrete both proteases of different classes
and their endogenous inhibitors; disturbances in the
balance of proteases/inhibitors play the important role
in tumor growth and metastasizing processes (1). There-
fore, the search among secreted proteins of biological
fluids is of special interest. The changes in balance
protease/inhibitors (increased expression and activity of
proteases and decreased level of inhibitors) were shown in
several malignancies as a result of increased consumption
of inhibitors (7). Cystatin C was shown to be implicated in
the invasiveness of human glioblastoma cells and as a
result, sense transcripts of cystatin C may prove useful in
cancer therapy. However, in some hemoblastoses (lym-
phoma, lymphogranulomatosis) opposite data were ob-
tained: increased serum cystatin C level was revealed,
and  decreased cystatin C concentration in acute leukosis
(9). Cystatin C belongs to known secreted inhibitors
among the cystatin superfamily, which includes both
extracellular and intracellular types of inhibitors of
cysteine proteases. Cystatin C was shown to be secreted
by different cell types, especially by activated macro-
phages, as well as by some tumor cells (3).
The tear proteins play an important role in maintain-
ing the ocular surface, and changes in their components
Table I. Cystatin C concentrations (ng/mL) in biological ﬂuids in choroidal melanoma and benign eye tumors (m9SEM)
Biological sample Control Choroidal melanoma Benign tumors and pseudo-tumorous disorders
Tear fluid (eye with tumor)  461.3917.2**#
(n42)
471.5915.5**
(n11)
Tear fluid (eye without tumor) 371.3925.7#
(n24)
496.6923.9**#
(n33)
477.5917.4**
(n11)
Anterior camera fluid 765.6991.1#
(n4)
585.9972.1*#
(n11)

Blood serum 950.4921.2
(n10)
1212.9992.5*
(n16)
778.8
*pB0.05, **pB0.001 versus the appropriate control.
#pB0.001 versus serum of the same group. The number of patients is given in parenthesis.
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surface. Tears can be used to study the proteomic
responses in patients with inflammatory eye disorders,
such as fungal keratitis (20) and possibly in tumor eye
disorders. The proteomic analysis of tear fluids in healthy
persons already showed some promising results in eye
research; 491 proteins were identified, revealing a large
number of proteases and protease inhibitors, such as
cystatins B, C, SA, SN, S (21). In our study, cystatin C
and lactoferrin levels in tear fluid of patients with
choroidal melanoma did not relate with the size of the
tumor and their localization. Further studies are neces-
sary to reveal the role of other types of cystatins (such as
cystatins CN, S) in eye fluids, which can be useful in
differential diagnosis of eye malignancies. Cystatin C is
present in high concentrations in the normal human and
rat retinas and similarly expressed in normal human and
mouse retinas; it was suggested that cystatin C could be
involved in the regulation of photoreceptor degradation
in retinas (11). Cystatin C also reveals some immunomo-
dulatory activity, playing a role in antigen presentation
(4,22). According to some experimental data, uptake of
cystatin C by eye cells has been shown (11). In experi-
ments in mice and rats, it was shown that cystatin C
administered intravitreally in vivo is taken up into cells of
the corneal endothelium and epithelium, the epithelial
cells lining the ciliary processes and into cells in the
neuroretina and the retinal pigment epithelium (11,12).
The active, temperature-dependent uptake of cystatin C
into several cell types (the same that contain endogenous
cystatin C) in the cornea, ciliary body and retina was
noted (11). The uptake of cystatin C indicates that the
inhibitor may exert biological functions in intracellular
compartments. It is also possible that this uptake system
may regulate the extracellular levels of cystatin C in the
eye (11,12). Possibly, there is the potential to use cystatins
in the therapy of different eye disorder (including eye
tumor) to increase the host cell resistance.
Conclusion
Tear cystatin C and lactoferrin level, increased in malig-
nant and benign eye tumors, seems to be a perspective for
diagnostics in these disorders. However, it is impossible to
differentiate choroidal melanoma and benign eye tumors
according to the level of cystatin C and lactoferrin in eye
tear fluids.
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